A Potential Psychedelic and COVID Therapy Play…All in One Stock

The global concern over the ongoing coronavirus pandemic isn’t going away and even the White House’s health advisor is concerned about what protection a potential vaccine may deliver…but…could there be an answer in a drug that already exists? 

With a focus on the R-and-D of therapeutics for infectious diseases and rare disorders, specialty life sciences Company Revive Therapeutics Ltd. (CSE: RVV, OTC: RVVTF, Forum) is advancing development on what could potentially be a major windfall as the world continues to grapple with the COVID-19 coronavirus pandemic. 

The Company is taking advantage of several F-D-A incentives to explore the use of Bucillamine (boo-SILL-ih-mine) for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. Revive Therapeutics also just made news when it filed its Clinical Trial Application with Health Canada. 

Stockhouse Editorial’s Dave Jackson was joined by Revive Therapeutics CEO Michael Frank and Derrick Welsh, Founder and C-O-O of Psilocin Pharma Corp, to talk more about what amazing possibilities Bucillamine could offer, future investment opportunities in the exploding magic / mushroom / psilocybin space, and to learn more about their companies in general.